We hypothesized that the activation of the PI3K pathway in combination with Ras/MAPK pathway, via PTEN loss and overexpression of activated KRAS, respectively, is sufficient to promote tumor initiation and progression in a non-tumorigenic cell line. The gene discussed is KRAS; the disease is neoplasm.